Elicio Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Experts presented rare complete responses in metastatic KRAS-mutated pancreatic cancer after ELI-002 and checkpoint inhibitor therapy, supported by translational data showing durable, polyfunctional T cell responses and antigen spreading. A staged clinical development plan is underway to validate these findings in prospective trials.
-
AMPLIFY-7P phase II did not meet its primary endpoint but showed a strong treatment effect and immune response in R0 resected pancreatic cancer patients, informing a precision medicine phase III strategy focused on this group and extended dosing. The safety profile was favorable, and broader applications in KRAS-driven cancers are anticipated.
-
The AMP platform is advancing immunotherapeutics targeting KRAS and other mutations, with ELI-002 showing robust immune responses and improved survival in early trials. Phase II results in adjuvant pancreatic cancer are expected mid-2026, with strong financial support for ongoing development.
-
The company presented updates on its AMP platform for lymph node-targeted immunotherapies, highlighting strong clinical results for ELI-002 in KRAS-mutant cancers, robust T cell responses, and a favorable safety profile. Phase II results are expected in H1 2026, with plans for pipeline expansion and a Phase III trial.
Fiscal Year 2025
-
AMP vaccine technology enables potent immune responses by targeting lymph nodes, with ELI-002 showing strong safety, robust T cell activation, and promising early clinical signals in KRAS-mutant pancreatic cancer. The phase 2 trial is fully enrolled, with interim analysis expected in Q3.